Brazil - Brazzil Mag - Tested in Brazil New Vaccine Works on Cervical Cancer
Advertisement
  Saturday, 28 November 2009 
Main Menu
Home
News
Back Issues
Advertising
Contact Us
Brazil Forum
Magazine
Brazzil Classic
Yellow Pages
Classifieds
Images
BrazzilMag Newsfeed
Custom Search
Amazon Body Care
-------------
Brazil /Organic personal skin care wholesale / Brazil
--------------
Who's Online
We have 140 guests online
Latest News
Statistics
Members: 494
News: 11482
Web Links: 0
User Menu
Your Details
Submit News
Check-In My Items
My Comments
Login Form





Lost Password?
No account yet? Register
Most Read
Related Items
Contribution
Have you got news?

Do you have news, comment or story on Brazil you want to share with Brazzil? Just send it our way to brazzil@brazzil.com.

 
The Latest from Brazzil Magazine
Home
Tested in Brazil New Vaccine Works on Cervical Cancer PDF Print E-mail
Written by Newsroom   
Wednesday, 06 April 2005

Gardasil, the investigational vaccine against Human Papillomavirus (HPV) from Merck & Co., Inc., significantly reduced the combined incidence of persistent HPV 6, 11, 16, or 18 infection and related diseases, including new cervical pre-cancers and genital warts compared to placebo in a Phase II study published for the first time in The Lancet Oncology.

"The level of protection in this study against infection with these four HPV types, including pre-cancerous lesions, was significant," said the study's lead investigator, Luisa Villa, PhD, head of the Virology Group at the Ludwig Institute for Cancer Research, São Paulo, Brazil branch.

This phase II, randomized, double-blind, placebo-controlled study evaluated the efficacy of Gardasil in preventing infection from the types of HPV responsible for 70 percent of all cases of cervical cancer and 90 percent of all cases of genital warts.

In the study, 552 women in the United States, Europe and Brazil between the ages of 16 and 23 were randomized to receive vaccine or placebo at Day 1, Month 2, and Month 6.

The primary endpoint of the study was to assess the efficacy of the investigational vaccine in reducing the combined incidence of persistent HPV 6, 11, 16, and 18 infections and related diseases, including cervical pre-cancers (cervical intraepithelial neoplasia, or CIN), cervical cancer, and/or external genital lesions (genital warts).

Over the two and a half years of follow-up after vaccination, Gardasil reduced the combined incidence of persistent infection from HPV 6, 11, 16, or 18 and related genital disease including new cervical pre-cancers and genital warts by 90 percent compared with placebo among women who were naive to the relevant HPV types at baseline (p<0.001).

Thirty-six cases of either disease, persistent infection, or detection of HPV on the last visit on record were seen in the placebo group compared to four in the group who received Gardasil.

Of the four cases seen in the group who received Gardasil, one was confirmed as persistent infection; in the other three cases HPV was detected on the last study visit but was not later confirmed as a persistent infection.

The women who participated in this study were randomized to receive either the vaccine or the placebo at day 1, month 2 and month 6. At regular intervals for 30 months following the 6-month vaccine or adjuvant-containing placebo regimen, the participating women underwent gynecologic examination and sampling to determine HPV status.

"This study evaluated the effectiveness of Gardasil in reducing the combined incidence of persistent HPV infections and related diseases, including new cervical pre-cancers and genital warts caused by HPV 6, 11, 16 and 18," said Kevin Ault, MD, Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine.

"Although the study was not originally designed or powered to assess vaccine efficacy on the disease endpoints separately, efficacy of the investigational vaccine against cervical pre-cancers caused by the HPV types 16 18, 6 and 11 was 100 percent."

Adverse events related to the injection site were higher among those who received Gardasil compared with placebo recipients. The most common injection site and systemic adverse events were pain and headache, respectively. None of the subjects who received the investigational vaccine discontinued the study due to an adverse experience.

In this study, vaccination with Gardasil induced an immune response as measured by anti-HPV serum antibody titers. Anti-HPV 6, 11, 16 and 18 geometric mean titers (GMTs) at the completion of the vaccine regimen (month 7) were substantially higher among vaccinated women than among placebo-recipients with a previous history of natural HPV infection.

Although antibody levels among the women vaccinated with Gardasil started to decline after month 7, at month 36 they still remained at or above those observed in women in the placebo group who had an immune response to a previous natural HPV infection.

Phase III clinical trials to evaluate Gardasil are currently underway with over 25,000 participants enrolled worldwide. Phase III data are expected to be available later this year.

Cervical Cancer, HPV and Genital Warts

It is estimated that approximately 20 million American men and women are infected with HPV. In most people, HPV appears to go away on its own. In some, the virus has been linked to cervical cancer, abnormal pap tests and genital warts.

In the United States, an estimated 10,370 new cases of cervical cancer will be diagnosed in 2005, and there will be an estimated 3,710 deaths from cervical cancer. Genital warts are common - 500,000 to 1,000,000 cases in the United States alone - and treatment options may be painful.

"HPV types 6 or 11 are not linked to cervical cancer, but they can cause abnormal Pap smears, which then lead to additional tests - and unnecessary worries about cancer," said Eliav Barr, MD, senior director of Clinical Research, Merck Research Laboratories, and a co-author of the study.

"Gardasil was purposefully designed to target the HPV types most commonly associated with cervical cancer, as well as the types that cause genital warts and many abnormal Pap smears, to reduce the burden from HPV infection as much as possible."

In 1995, Merck entered into a license with CSL Limited relating to technology used in Gardasil.

Merck & Co., Inc.
www.merck.com

Hits: 6075
Comments (2)Add Comment
Gardasil for 40 years old wonam
written by Clarissa Rodrigues, July 29, 2006
My last exam showed me HPV positiv B for Vilve RLU/PCA:0.43 RLU/PCB:122.00; Vagina positive B, RLU/PCA:0.31 RLU/PCB: 156.00 and Colo RLU/PCA: 0.16 , RLU/PCB: 3.91. Without lesions.
Is there one vacine like Gardasil for woman 40 years old ? In my case one vacine can avoid Cancer ???
If ther one vacine, how can I buy it? Please help me with informations.
Best regards,
Clarissa Rodrigues
clarissa.rodrigues@volkswagen.com.br
report abuse
vote down
vote up
Votes: +0
...
written by Gloria Watts, August 09, 2007
I would like more information e-mailed to me. I believe this is the answer to my daughter's problems. She is 25 years old and has and is suffering from fibroid tumors on her uterus. Several of her aunts on her father's side of the family has died from cervical cancer.
report abuse
vote down
vote up
Votes: +0

Write comment
quote
bold
italicize
underline
strike
url
image
quote
quote
smile
wink
laugh
grin
angry
sad
shocked
cool
tongue
kiss
cry
smaller | bigger

security code
Write the displayed characters


busy




Reddit!Del.icio.us!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Newsvine!Furl!Yahoo!Ma.gnolia!Add this social bookmarking functionality to your website! title=
 
< Prev   Next >
Brazzil Magazine on Twitter


Visit Brazzil Social with Video, Music and Chat


Home
Brazzil Magazine - Since 1989 trying to understand Brazil
  • Poor Women from Northeast Brazil Learn Joy of Meeting and Helping Each Other


    Joined hands The small, coastal town of Condé is located just a twenty minute's drive from João Pessoa, the capital of Paraíba. The Northeast of Brazil has historically been a place of encounter and mixing between peoples. For millenia groups of indigenous people fished, farmed, migrated and sometimes fought along this large, fertile area.

  • Ahmadinejad's Visit: Iran, Honduras and Brazil's Hypocrisy in Dealing With Them


    Ahmadinejad and Lula The Brazilian diplo-MÁ-cia (bad diplomacy) carries on its accelerated course towards the non-acknowledgment of human rights, although sometimes it takes pleasure in saying that it does precisely the opposite. The visit of Iran's president, Mahmoud Ahmadinejad, is another example of a diplomatic omission that verges on hypocrisy.

  • Lula Is About to Fulfill His Wish of Getting His Good Friend Chavez in Mercosur


    Lula and Chavez On July 4, 2006, representatives of Argentina, Brazil, Paraguay and Uruguay met in Caracas to sign the protocol for the entrance of Venezuela into the Southern Common Market (Mercosur). After two and a half years, the protocol was approved by the legislative bodies of Argentina and Uruguay, and as of now it may be only days away from being ratified by the continent's economic megalith, Brazil.

  • Denying Education is the Other AIDS. And Brazil Is Guilty of Inflicting It


    Children from a Diadema band Some sectors of the fight against AIDS have suggested that Thabo Mbeki, the former president of South Africa, committed genocide through his absence from the fight against the illness in his country throughout his two terms.

  • Child Labor Went Down in Brazil, But 5 Million Underage Workers Are Still Way Too Many


    Child labor in Brazil One hundred and eleven years after Brazil abolished slavery, the number of workers deprived of their freedom is still huge. They raise cattle, produce charcoal, sugar cane or timber. Some of them, most undocumented Bolivians, work in basements of small apparel factories in São Paulo and other metropolis.

  • Some Humility Would Do Lula Good. On Human Rights Brazil Has Long Way to Go


    A prison in Rio de Janeiro, Brazil On November 7, 2009 a few friends and I had an opportunity to take a look inside a Brazilian jail outside the city of Rio de Janeiro. We were able to take some amateur footage of our experience on video (see link below). It's no surprise, of course, that the typical Brazilian jail lacks some of the functionality of those in North America or Europe, but our experience that day was quite shocking.

  • Brazil's Amazon Rainforest Policy Is a One-Way Road to Disaster


    Trasamazonian road in BrazilDepletion of the Amazon Rainforest is not a new concern facing environmentalists, biologists, ecologists, and a growing number of the Amazonian indigenous peoples. For decades they have feared for the fate of the world's most biologically diverse and species-rich hothouse.

  • Geisy, Brazil's Miniskirt Student, Should Try US College Next Year


    Geisy Arruda from BrazilGeisy Arruda made history this week in Brazil, but for all the wrong reasons. What began as a poorly planned fashion statement has become a worldwide tale. Geisy decided to wear a pink mini-dress to her private college in São Paulo state, and after that, all hell broke loose.

  • Vigilante Groups in Brazil Trump Drug Gangs and Become Rio's New Authority


    Brazilian favela in Rio The push of vigilante groups in Rio de Janeiro's favelas (shantytowns) in the last three years is the most important and alarming information of the just-released study by the Rio de Janeiro University's Violence Research Center (Nupev-Uerj).

  • Brazil Police Use Press Coverage as Green Light to Kill and Invade Houses in Rio


    Rio police in a favela A dispute over drug trafficking territory in Rio de Janeiro has intensified lately, leaving in its wake unprecedented acts of violence, such as the downing of a police helicopter in the northern zone of the city on October 17.  Three policemen died and another two were injured.  This event has drawn the attention of the international media, who are raising the issue of public security for the 2016 Olympics to be held in Rio.